Healthcare and Life Sciences

Healthcare and Life Sciences

Selendy Gay partners serve as national or lead trial counsel in cutting-edge healthcare and life sciences disputes across the country and around the world. Our firm brings to bear its deep knowledge of the two industries, combined with our courtroom and arbitration skills, when representing both plaintiffs and defendants. We grasp our clients’ businesses quickly and thoroughly and weaponize that knowledge on our clients’ behalf.


Selendy Gay represents players in the healthcare sector, from insurance companies, to insurance administrators, to financial services companies investing in the industry. Our representative engagements include:

  • UMB Bank, as Trustee for holders of Celgene contingent value rights (“CVRs”), seeking over $6 billion in damages arising from Bristol Myers’ alleged failure to timely secure regulatory approval for the drugs associated with the CVR payout.
  • SaveOnSP, which provides cost-saving strategies for self-funded employers, against a $100 million suit by Johnson & Johnson alleging tortious interference and violations of New York’s General Business law in connection with copay assistance strategies.
  • A global health insurance service company, in defense against a $100 million ERISA, RICO suit, and breach-of-contract suit. We won a summary judgment dismissing all claims brought by a medical center alleging the underpayment of network reimbursements.
  • A global health insurance service company, in defense against an over-$1 billion ERISA, antitrust, and RICO suit. We won rulings dismissing provider plaintiffs and refusing class certification for subscribers alleging misuse of database for reimbursement of out-of-network claims.
  • The owner of a health insurance claim-editing service in potential contract dispute with a business partner. The client’s claim stemmed from the violation of an exclusivity provision when the business partner acquired a direct competitor. The business partner’s acquisition, in turn, led to an antitrust enforcement action, where the non-party client retained our firm to prevent disclosure of confidential material appearing in trial exhibits.

Life Sciences

Selendy Gay has deep roots in the life sciences industry, representing global pharmaceutical companies, biotechnology start-ups, parties in a joint venture, and major investors in the sector. Our representative engagements include:

  • A medical device company subject to a U.S. Department of Justice investigation related to insurance reimbursement claims it submitted on behalf of customers covered by federal employee health plans. Through a series of presentations to the DOJ, we demonstrated that this was not a criminal matter and successfully had the case transferred to the civil division. Ultimately, we settled on terms that were favorable to the client.
  • A biotechnology company in  obtaining a judgment dismissing a complex patent infringement suit brought by a multinational pharmaceutical company that sought over $500 million in damages.
  • The former stockholders of the robotic medical devices company Auris Health in a $2.35 billion earn-out suit against Johnson & Johnson and its subsidiary Ethicon in the Delaware Court of Chancery, in an action centered around the acquirer’s post-merger failures to achieve regulatory and net sales milestones.
  • A large Chinese pharmaceutical company in connection with an affiliated drug discovery start-up accused of misappropriating trade secrets.
  • The CEO of a public medical technology company in a special committee investigation about allegations of pay inequity.
  • A multinational pharmaceutical company, in seeking reargument or leave to appeal to the New York Court of Appeals from an order affirming the denial of a motion to dismiss on forum non conveniens grounds in an asbestos case brought by U.K. plaintiffs arising out of their use of cosmetics products in the U.K.
  • A leading biotechnology company, in a contract dispute with its joint venture partner relating to liability for the costs for their product’s clinical trials.
  • A manufacturer of pharmaceutical injectables and biosimilars, in shareholder fiduciary duty and securities litigation brought in Illinois Chancery Court and the Northern District of Illinois relating to the acquisition of a company. Defeated preliminary injunction and the case was voluntarily withdrawn.
  • A dermatologic pharmaceuticals company, in providing advice regarding potential arbitration following the sale of a patent of a topical skin treatment and the subsequent breach of the duty to reasonably market and commercialize the product.
  • A joint venture between two global pharmaceutical companies – with milestones required for the development, licensing and marketing of a new drug – in a billion-dollar ICC arbitration.
  • A life sciences hedge fund in an arbitration relating the departure of its founding partner.
  • A pharmaceutical company in arbitration against a former contract partner in connection to the partner’s submission of an ANDA in violation of the terms of a pre-existing Distribution and Supply Agreement.